Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Comment by C10H12N2on Apr 07, 2023 6:43am
84 Views
Post# 35384423

RE:HUGE NEWS : $4 MILLION IN FUNDING FROM NRC

RE:HUGE NEWS : $4 MILLION IN FUNDING FROM NRCThe timeline for Arch's use of 4M in government funding is one that throws everything at the wall everywhere all at once. The probability of Arch ever getting to an FDA approval remains a very tall task at best. Better than 99% of any drug tied to any COVID-19 clinical trial - for any clinical reason - that's registered anywhere around the world - has secured zero (0) commercialization approvals from any regulatory agency including the FDA ("The Gold Standard"). Arch's latest funding news release is merely a carbon copy of their last government funding news release. Meanwhile, time waits for no one as the world moves towards the next global pandemic.

Godspeed 
<< Previous
Bullboard Posts
Next >>